Format

Send to

Choose Destination
Acta Neurol Scand. 2013 Jul;128(1):65-72. doi: 10.1111/ane.12081. Epub 2013 Feb 13.

Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial.

Author information

1
Department of Neurology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India. jayanteek@yahoo.com

Abstract

OBJECTIVE:

This study compares efficacy and safety of divalproate extended release (DVA-ER) and amitriptyline (AMT) in migraine.

MATERIALS AND METHODS:

Three hundred migraineurs having >4 attacks monthly were randomized into DVA-ER or AMT. The primary end points were >50% reduction in frequency, ≥1 grade improvement in the severity, and >50% improvement in a visual analogue scale (VAS). Secondary end points were functional disability, rescue medication, and adverse events.

RESULTS:

The median age was 32 years, and 241 were women. 150 patients each received DVA-ER and AMT. At 3 months, 74.7% in DVA-ER and 62% patients in AMT group improved in headache frequency (P = 0.02) and at 6 months, 65.3% and 54%, respectively (P = 0.90). At 3 months, the VAS score improved by >50% in 80.7% in DVA-ER and 64% in AMT (P = 0.005). At 6 months, there was no significant difference between the two groups in VAS score (69.3% vs 56%; P = 0.47) and other outcome parameters. The composite side effects were also not different between the two groups (68% vs 81%); however, hair fall, menstrual irregularity, polycystic ovary, and weight gain were commoner in DVA-ER group.

CONCLUSION:

Divalproate extended release is more effective at 3 months than AMT; however, at 6 months, both are equally effective in migraine prophylaxis.

PMID:
23406477
DOI:
10.1111/ane.12081
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center